PATHOLOGICAL COMPLETE RESPONSE WITH PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR NEOADJUVANT TREATMENT OF EARLY TRIPLE NEGATIVE BREAST CANCER: A SINGLECENTER PROSPECTIVE STUDY FROM BANGLADESH

This observational study is aimed to find out the
Pathological Complete Response (pCR) at the time of definitive
surgery who had received chemotherapy along with Pembrolizumab
as neoadjuvant settings. After the definitive surgery
the biopsy was observed and based on the reports the
response was documented as pCR.

Results Among the 6 patients the age range is 37-75 years
and only 2 was right sided where the 4 is left sided breast
primary. The stage was 50% (3) for stage III and 50% (3)
were stage II. Histological Grade ranging of moderate differentiated
mostly 4 case where 2 was G-III. All the 5-case had
high Ki-67 and only 1 had low (8%). All these 6 cases
received NACT settings with 3 weekly 8 cycles of Pembrolizumab
200mg with Weekly Paclitaxel + Carboplatin weekly for
12 weeks followed by 3 weekly Anthracycline + Cyclophosphamide
for 4 cycles. After definitive surgery 2 by MRM
whereas rest 4 had lumpectomy with Sentinal LN biopsy or
axillary dissection. Post operative histopathology confirm the
treatment response by complete pathological response pCR by
5 cases (83.33%) except 1 (16.67%)

pCR is the primary denominator for TNBC cases
and it is around 50-70 percents of the study populations. In
this small observational study, we also noticed the excellent
outcome in regards of pCR by adding the Pembrolizumab efficacy.
But further larger inclusions of cases and head-to-head
comparative study can show some additional results and needs
further study to see the pCR outcomes in Bangladeshi populations.
This is the first documented data that is like higher in
pCR in comparison to KEYNOTE 522.